Clinical Trials Directory

Trials / Completed

CompletedNCT00964873

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
29 (actual)
Sponsor
Synta Pharmaceuticals Corp. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML.

Conditions

Interventions

TypeNameDescription
DRUGSTA-9090 (ganetespib)Chemotherapy agent

Timeline

Start date
2009-08-01
Primary completion
2010-12-01
Completion
2011-08-01
First posted
2009-08-25
Last updated
2014-09-18

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00964873. Inclusion in this directory is not an endorsement.